$CLRB

Cellectar Biosciences (CLRB) reported Q2 earnings, highlighting strong clinical data for iopofosine and a clear regulatory path. The CLOVER-WaM study showed high response rates in Waldenstrom’s macroglobulinemia. The company plans a Phase III trial and accelerated approval submission in 2027. Financing of up to $140M was secured, improving cash position to $34M. R&D expenses increased, widening net loss to $6.9M. Management acknowledged dilution risks and operational challenges.

Cellectar Biosciences (CLRB) reported Q2 2026 earnings with $34M in cash, up from $13.2M at year-end 2025. The company raised $31.7M net from a May 2026 financing, with potential for $140M total. R&D expenses increased to $4.6M, while net loss was $6.9M. Clinical data showed promising results for iopofosine I 131 in Waldenstrom's macroglobulinemia, with a 79.2% response rate in post-BTKi patients. The company plans to initiate a Phase 3 trial by late 2026 or early 2027, targeting mid-2027 NDA su

Cellectar Biosciences (CLRB) reported Q2 2026 results on an earnings call, including $34.0M cash at June 30, 2026, $4.6M R&D expense, and a $6.9M net loss ($0.57/share). Management discussed Phase 3 WM site activation, targeted accelerated-approval submission in March-April 2027, CLR 125 data later in 2026/early 2027, and actinium-225 multi-sourcing. The May financing added $35M upfront plus milestone warrants up to $105M.

Cellectar Biosciences (CLRB) reported Q2 2026 results. Cash and cash equivalents were $34.0M as of June 30, 2026, funding operations into Q2 2027. R&D rose to $4.6M from $2.4M a year earlier; net loss was $6.9M, or $0.57/share. Pipeline progress includes Phase 3 prep for Iopofosine I 131 in Waldenström macroglobulinemia and Phase 1b enrollment for CLR 125 in triple-negative breast cancer.

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 2026 results and corporate updates. It initiated site activation for a Phase 3 confirmatory trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA planned for mid-2027 under FDA Accelerated Approval. ASCO data showed 79.2% MRR (n=24) post-BTKi. CLR 125 Phase 1b TNBC enrollment began. Cash was $34.0M at June 30, 2026.

Cellectar Biosciences, Inc. (CLRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Appro

Cellectar Biosciences (NASDAQ: CLRB) said a Phase 1 open-label study of iopofosine I 131 plus low-dose dexamethasone in 31 relapsed or refractory multiple myeloma patients was published in Cancers. Among 26 efficacy-evaluable patients, 84.6% had stable disease or better, with a 30% overall response rate in those receiving at least 60 mCi. Safety was manageable, mainly reversible cytopenias.

Cellectar Biosciences, Inc. (CLRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2620219d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CELLECTAR BIOSCIENCES, INC. 2021 STOCK INCENTIVE PLAN, AS AMENDED SECTION 1. General Purpose of the Plan; Definitions The purpose of this 2021 Stock Incentive Plan (the “Plan”) is to encourage and enable officers and empl

Cellectar Biosciences has appointed Andrew Gu as a Class III director and Audit Committee member to its board, effective May 18, 2026. Concurrently, Stefan D. Loren has chosen not to seek reelection but will transition to a consulting role for one year starting July 8, 2026, where he will be compensated quarterly and granted stock options. Gu, an analyst at Nantahala focusing on biotech investments, was selected by Nantahala for the board position.

Cellectar Biosciences, Inc. (NASDAQ: CLRB) Chief Operating Officer Jarrod Longcor recently increased his holdings by purchasing 8,680 shares of common stock at $2.88 per share and 26,040 warrants at $0.01 per warrant. These open-market transactions, which occurred on May 7, 2026, increased his direct ownership to 20,451 common shares and 36,149 warrants. The warrants are exercisable for common stock at $2.88, with varying expiration terms of one, two, and five years from stockholder approval.